Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells

Marija Balic, Nadine Rapp, Stefanie Stanzer, Henry Lin, Jasmin Strutz, Joanna Szkandera, Maria Grazia Daidone, Hellmut Samonigg, Richard James Cote, Nadia Dandachi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: The phenotypical and functional variety of breast cancer cells is well recognized. This variety is evident in primary tumors and in disseminated tumor cells (DTCs) and solid metastases as shown for recognized prognostic factors, such as estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2/neu and also for cancer stem cell markers such as CD44, CD24, or aldehyde dehydrogenase (ALDH). For the development of new therapeutic strategies, the identification and characterization of disseminated breast cancer cells are needed. This requires the use of multiple antibodies (ie, cytokeratin, Her2/neu, ALDH1, CD44, and CD24) labeled with fluorochromes of different colors and spectral image analysis to separate different color spectra. Methods: We have focused here on putative breast cancer stem cell markers and evaluated the feasibility of triple and quadruple labeling of breast cancer cells. Using breast cancer cell lines we have developed a method optimized for multimarker analysis by employing novel DyLight Technology. Single marker immunofluorescence was performed in 6 replicates, and reproducible results had to be obtained before proceeding to multimarker immunofluorescence. Results: Three of the markers, CD44, ALDH1, and cytokeratin have been directly conjugated with DyLight dyes. CD24 could not be conjugated directly to the fluorescent dye. A labeled secondary antibody was used for visualization. Single and multimarker immunofluorescence gave consistent results throughout the replicates. Conclusions: This novel protocol will facilitate detection and phenotypical characterization of disseminated tumor cells. In addition, by adding additional markers, distinct subpopulations could be evaluated for the expression of particular therapeutic targets.

Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalApplied Immunohistochemistry and Molecular Morphology
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Neoplastic Stem Cells
Fluorescent Antibody Technique
Breast Neoplasms
Keratins
Fluorescent Dyes
Color
Neoplasms
Aldehyde Dehydrogenase
Antibodies
Progesterone Receptors
Estrogen Receptors
Coloring Agents
Neoplasm Metastasis
Technology
Cell Line
Therapeutics

Keywords

  • ALDH1
  • breast cancer stem cells
  • CD24
  • CD44
  • disseminated tumor cells
  • Multimarker immunofluorescence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. / Balic, Marija; Rapp, Nadine; Stanzer, Stefanie; Lin, Henry; Strutz, Jasmin; Szkandera, Joanna; Daidone, Maria Grazia; Samonigg, Hellmut; Cote, Richard James; Dandachi, Nadia.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 19, No. 1, 01.2011, p. 33-40.

Research output: Contribution to journalArticle

Balic, Marija ; Rapp, Nadine ; Stanzer, Stefanie ; Lin, Henry ; Strutz, Jasmin ; Szkandera, Joanna ; Daidone, Maria Grazia ; Samonigg, Hellmut ; Cote, Richard James ; Dandachi, Nadia. / Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. In: Applied Immunohistochemistry and Molecular Morphology. 2011 ; Vol. 19, No. 1. pp. 33-40.
@article{37224ac47f654603b212ac2286d77b08,
title = "Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells",
abstract = "Purpose: The phenotypical and functional variety of breast cancer cells is well recognized. This variety is evident in primary tumors and in disseminated tumor cells (DTCs) and solid metastases as shown for recognized prognostic factors, such as estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2/neu and also for cancer stem cell markers such as CD44, CD24, or aldehyde dehydrogenase (ALDH). For the development of new therapeutic strategies, the identification and characterization of disseminated breast cancer cells are needed. This requires the use of multiple antibodies (ie, cytokeratin, Her2/neu, ALDH1, CD44, and CD24) labeled with fluorochromes of different colors and spectral image analysis to separate different color spectra. Methods: We have focused here on putative breast cancer stem cell markers and evaluated the feasibility of triple and quadruple labeling of breast cancer cells. Using breast cancer cell lines we have developed a method optimized for multimarker analysis by employing novel DyLight Technology. Single marker immunofluorescence was performed in 6 replicates, and reproducible results had to be obtained before proceeding to multimarker immunofluorescence. Results: Three of the markers, CD44, ALDH1, and cytokeratin have been directly conjugated with DyLight dyes. CD24 could not be conjugated directly to the fluorescent dye. A labeled secondary antibody was used for visualization. Single and multimarker immunofluorescence gave consistent results throughout the replicates. Conclusions: This novel protocol will facilitate detection and phenotypical characterization of disseminated tumor cells. In addition, by adding additional markers, distinct subpopulations could be evaluated for the expression of particular therapeutic targets.",
keywords = "ALDH1, breast cancer stem cells, CD24, CD44, disseminated tumor cells, Multimarker immunofluorescence",
author = "Marija Balic and Nadine Rapp and Stefanie Stanzer and Henry Lin and Jasmin Strutz and Joanna Szkandera and Daidone, {Maria Grazia} and Hellmut Samonigg and Cote, {Richard James} and Nadia Dandachi",
year = "2011",
month = "1",
doi = "10.1097/PAI.0b013e3181ebf4e8",
language = "English",
volume = "19",
pages = "33--40",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells

AU - Balic, Marija

AU - Rapp, Nadine

AU - Stanzer, Stefanie

AU - Lin, Henry

AU - Strutz, Jasmin

AU - Szkandera, Joanna

AU - Daidone, Maria Grazia

AU - Samonigg, Hellmut

AU - Cote, Richard James

AU - Dandachi, Nadia

PY - 2011/1

Y1 - 2011/1

N2 - Purpose: The phenotypical and functional variety of breast cancer cells is well recognized. This variety is evident in primary tumors and in disseminated tumor cells (DTCs) and solid metastases as shown for recognized prognostic factors, such as estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2/neu and also for cancer stem cell markers such as CD44, CD24, or aldehyde dehydrogenase (ALDH). For the development of new therapeutic strategies, the identification and characterization of disseminated breast cancer cells are needed. This requires the use of multiple antibodies (ie, cytokeratin, Her2/neu, ALDH1, CD44, and CD24) labeled with fluorochromes of different colors and spectral image analysis to separate different color spectra. Methods: We have focused here on putative breast cancer stem cell markers and evaluated the feasibility of triple and quadruple labeling of breast cancer cells. Using breast cancer cell lines we have developed a method optimized for multimarker analysis by employing novel DyLight Technology. Single marker immunofluorescence was performed in 6 replicates, and reproducible results had to be obtained before proceeding to multimarker immunofluorescence. Results: Three of the markers, CD44, ALDH1, and cytokeratin have been directly conjugated with DyLight dyes. CD24 could not be conjugated directly to the fluorescent dye. A labeled secondary antibody was used for visualization. Single and multimarker immunofluorescence gave consistent results throughout the replicates. Conclusions: This novel protocol will facilitate detection and phenotypical characterization of disseminated tumor cells. In addition, by adding additional markers, distinct subpopulations could be evaluated for the expression of particular therapeutic targets.

AB - Purpose: The phenotypical and functional variety of breast cancer cells is well recognized. This variety is evident in primary tumors and in disseminated tumor cells (DTCs) and solid metastases as shown for recognized prognostic factors, such as estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2/neu and also for cancer stem cell markers such as CD44, CD24, or aldehyde dehydrogenase (ALDH). For the development of new therapeutic strategies, the identification and characterization of disseminated breast cancer cells are needed. This requires the use of multiple antibodies (ie, cytokeratin, Her2/neu, ALDH1, CD44, and CD24) labeled with fluorochromes of different colors and spectral image analysis to separate different color spectra. Methods: We have focused here on putative breast cancer stem cell markers and evaluated the feasibility of triple and quadruple labeling of breast cancer cells. Using breast cancer cell lines we have developed a method optimized for multimarker analysis by employing novel DyLight Technology. Single marker immunofluorescence was performed in 6 replicates, and reproducible results had to be obtained before proceeding to multimarker immunofluorescence. Results: Three of the markers, CD44, ALDH1, and cytokeratin have been directly conjugated with DyLight dyes. CD24 could not be conjugated directly to the fluorescent dye. A labeled secondary antibody was used for visualization. Single and multimarker immunofluorescence gave consistent results throughout the replicates. Conclusions: This novel protocol will facilitate detection and phenotypical characterization of disseminated tumor cells. In addition, by adding additional markers, distinct subpopulations could be evaluated for the expression of particular therapeutic targets.

KW - ALDH1

KW - breast cancer stem cells

KW - CD24

KW - CD44

KW - disseminated tumor cells

KW - Multimarker immunofluorescence

UR - http://www.scopus.com/inward/record.url?scp=78650803480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650803480&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181ebf4e8

DO - 10.1097/PAI.0b013e3181ebf4e8

M3 - Article

VL - 19

SP - 33

EP - 40

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 1

ER -